Publication: Age-related clinical outcomes of patients with non-valvular atrial fibrillation: Insights from the COOL-AF registry
1
Issued Date
2021-01-01
Resource Type
ISSN
11781998
11769092
11769092
Other identifier(s)
2-s2.0-85105517276
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Interventions in Aging. Vol.16, (2021), 707-719
Suggested Citation
Rungroj Krittayaphong, Thanita Boonyapiphat, Chaiyasith Wongvipaporn, Poom Sairat Age-related clinical outcomes of patients with non-valvular atrial fibrillation: Insights from the COOL-AF registry. Clinical Interventions in Aging. Vol.16, (2021), 707-719. doi:10.2147/CIA.S302389 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/78749
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Age-related clinical outcomes of patients with non-valvular atrial fibrillation: Insights from the COOL-AF registry
Other Contributor(s)
Abstract
Purpose: We aimed to compare the rate of clinical outcomes among three age groups (<65, 65-74, and ≥75 years) of adult patients with non-valvular atrial fibrillation (NVAF). Patients and Methods: We prospectively enrolled NVAF patients from 27 Thailand medical centers. The following were collected at baseline: demographic data, risk factors, comorbid conditions, laboratory data, and medications. The clinical outcomes were ischemic stroke (IS) or transient ischemic attack (TIA), major bleeding (MB), intracerebral hemor- rhage (ICH), heart failure (HF), and death. All events were adjudicated. Patients were categorized according to age group into three groups; age <65, 65-74, and ≥75 years. Results: Among the 3402 patients that were enrolled during 2014-2017, the mean age was 67.4 ±11.3 years, and 2073 (60.9%) were older. The average follow-up was 25.7±10.6 months. Oral anticoagulants were given in 75.4% of patients (91.1% of OAC was warfarin). The incidence rate of IS/TIA, MB, ICH, HF, and death was 1.43 (1.17-1.74), 2.11 (1.79-2.48), 0.70 (0.52-0.92), 3.03 (2.64-3.46), and 3.77 (3.33-4.24) per 100 person-years, respectively. The risk of IS/TIA, MB, ICH, HF, and death increased with age both before and after adjustment for potential confounders. Even though OAC reduced the risk of IS/TIA, it increased the risk of MB. Net clinical benefit (NCB) analysis favored oral anticoagulant (OAC) in the high-risk subset of older adults. Conclusion: Older adult NVAF patients had a significantly increased risk of IS/TIA, MB, ICH, HF, and death compared to younger NVAF before and after adjustment for potential confounders. Strategies to reduce overall risk, including OAC use and choice and integrated care, should be implemented.